Marshall Wace’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Marshall Wace’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-23,198	Closed	-$165K	–	2113
2020 Q1	$165K	Sell	23,198 -39,057	-63%	-$487K	﹤0.01%	1216
2019 Q4	$1.49M	Buy	+62,255	New	+$1.72M	0.01%	887
2016 Q3	–	Sell	-33,685	Closed	-$795K	–	1210
2016 Q2	$795K	Sell	33,685 -93,372	-73%	-$2.31M	0.01%	753
2016 Q1	$2.59M	Sell	127,057 -836,467	-87%	-$26.5M	0.03%	501
2015 Q4	$49.6M	Buy	963,524 +576,073	+149%	+$27.9M	0.47%	56
2015 Q3	$16.5M	Buy	387,451 +9,052	+2%	+$437K	0.2%	126
2015 Q2	$17.2M	Buy	378,399 +81,180	+27%	+$3.27M	0.22%	118
2015 Q1	$11.3M	Buy	+297,219	New	+$10.2M	0.15%	181
2014 Q3	–	Sell	-3,903	Closed	-$114K	–	1108
2014 Q2	$114K	Buy	+3,903	New	+$94.5K	﹤0.01%	894

Other funds holding PTLA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return

WIC

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return

Marshall Wace's PTLA Position: Q2 2020 in Review

Marshall Wace sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q2 2020, closing a stake of 23,198 shares — an estimated $165K sold.

Marshall Wace first reported a position in PTLA in Q2 2014 and held it in 9 quarters. The position peaked at $49.6M in Q4 2015. 162 funds tracked by Wall St. Rank hold PTLA as of Q2 2020.

Marshall Wace reported no remaining Portola Pharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
Marshall Wace sold 23,198 Portola Pharmaceuticals, Inc. shares in Q2 2020, an estimated $165K.
Marshall Wace first reported a position in Portola Pharmaceuticals, Inc. in Q2 2014 and held it in 9 quarters.
Marshall Wace's Portola Pharmaceuticals, Inc. position peaked at $49.6M in Q4 2015.
162 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q2 2020.

Based on Marshall Wace's 13F filing for Q2 2020, filed 13 Aug 2020.